Is Eflornithine-Hcl Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Eflornithine-Hcl? Is Eflornithine-Hcl safe for nursing mother and child? Does Eflornithine-Hcl extracts into breast milk? Does Eflornithine-Hcl has any long term or short term side effects on infants? Can Eflornithine-Hcl influence milk supply or can Eflornithine-Hcl decrease milk supply in lactating mothers?

• DrLact safety Score for Eflornithine-Hcl is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Eflornithine-Hcl may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Eflornithine-Hcl may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Eflornithine-Hcl .
• It is recommended to evaluate the advantage of not breastfeeding while using Eflornithine-Hcl Vs not using Eflornithine-Hcl And continue breastfeeding.
• While using Eflornithine-Hcl Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

African type anti-trypanosomal drug (T.Gambiense, Sleeping disease). Treatment is recommended for 7 days long. There is not any experience with this drug on breastfeeding to make a recommendation. Assess risk-benefit ratio and mother’s condition closely, which is usually precarious. In any case, check-up for side effects on both the mother and the baby. Because of such short-term treatment, a temporally breastfeeding withholding may be scheduled. Melarsoprol is a much less toxic drug, unfortunately, the industry do not regard it as being profitable enough to assure a continuing access of poor patients to the latter drug.